Trulicity

ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
Fierce Pharma
ADA
diabetes
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Flag link:
Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients
Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients
Pharmaceutical Business Review
Eli Lilly
Trulicity
FDA
type 2 diabetes
Cardiovascular
Flag link:
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
Fierce Biotech
diabetes
insulin
Mt Sinai
Novo Nordisk
Ozempic
Rybelsus
Victoza
Eli Lilly
Trulicity
AstraZeneca
Bydureon
Flag link:
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge
Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge
Pharmaforum
Eli Lilly
Trulicity
diabetes
Flag link:
Lilly counts on growing markets to boost lagging Taltz, Trulicity
Lilly counts on growing markets to boost lagging Taltz, Trulicity
Fierce Pharma
Eli Lilly
Trulicity
Taltz
immunology
type 2 diabetes
Flag link:
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Flag link:
How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
Investors Business Daily
Novo Nordisk
Eli Lilly
oral semaglutide
Trulicity
diabetes
Flag link:
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Yahoo/Zacks.com
Eli Lilly
clinical trials
type 2 diabetes
Trulicity
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
Endpoints
Novo Nordisk
Trulicity
Ozempic
Eli Lilly
diabetes
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
Despite Trulicity success, Lilly can't escape diabetes concerns
Despite Trulicity success, Lilly can't escape diabetes concerns
Biopharma Dive
Eli Lilly
diabetes
earnings
Trulicity
Flag link:
Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'
Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'
Endpoints
Eli Lilly
Trulicity
diabetes
Flag link:
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Endpoints
Eli Lilly
diabetes
Novo Nordisk
Ozempic
LY3298176
Trulicity
Flag link:
Trulicity’s turn to show a cardiovascular benefit
Trulicity’s turn to show a cardiovascular benefit
EP Vantage
Trulicity
Eli Lilly
Flag link:
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Flag link:
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
Fierce Pharma
Eli Lilly
Trulicity
diabetes
Novo Nordisk
Victoza
AstraZeneca
Bydureon
ADA
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Novo reveals more Ozempic data on change in body weight by baseline BMI
Novo reveals more Ozempic data on change in body weight by baseline BMI
Yahoo/Reuters
Novo Nordisk
diabetes
BMI
Ozempic
Eli Lilly
Trulicity
Flag link:
Lilly touts Ph3 data for once-weekly Type II diabetes medication
Lilly touts Ph3 data for once-weekly Type II diabetes medication
Drug Delivery Business News
Eli Lilly
diabetes
clinical trials
Trulicity
Flag link:

Pages